Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
NRX Pharmaceuticals Inc(NRXP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NRXP
10/08/2026: NRXP (2-star) is currently NOT-A-BUY. Pass it for now.
NRX Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system disorders, primarily bipolar depression. Its primary investment story hinges on the potential success of its lead candidate, NRX-101, which targets high-unmet-need psychiatric conditions. The company's main strength lies in its strategy of repurposing known compounds, though it faces significant financial, regulatory, and execution risks common to pre-commercial biotech firms. The stock is best suited for speculative growth investors who understand the high volatility associated with clinical trial outcomes. Investors should closely monitor clinical trial data readouts and the company's ability to maintain sufficient liquidity to support its R&D roadmap.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a speculative growth play dependent on future clinical milestones. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical data or regulatory news flow. |
| Value investor | Weak fit | Lack of earnings and product revenue makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital into R&D. |
| Low-risk investor | Weak fit | The company's clinical-stage status entails high volatility and risk of capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are subject to sharp price swings based on news. |
| Valuation risk | High | Valuations are highly speculative as there are no current product revenues. |
| Competition risk (psychiatric drugs) | High | The company faces intense competition from established pharmaceutical giants. |
| Business quality | Medium | The company is early-stage with an unproven commercial business model. |
| Dividend income | Low / none | There is no dividend income and none is expected in the near term. |
| Execution risk | High | Failure to achieve regulatory approval would significantly damage the business. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 216.51% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 125.56M USD | Price to earnings Ratio - | 1Y Target Price 38.5 |
Price to earnings Ratio - | 1Y Target Price 38.5 | ||
Volume (30-day avg) 631.5K shares | Beta 2.07 | 52 Weeks Range 1.62 - 5.05 | Updated Date 10/08/2026 |
52 Weeks Range 1.62 - 5.05 | Updated Date 10/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| CNS Pipeline Development | Clinical development of NRX-101 for bipolar depression. | The company aims to profit by successfully developing and commercializing new psychiatric drugs. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 34.25 | Enterprise Value 111.37M | Price to Sales(TTM) 36.99 |
Enterprise Value 111.37M | Price to Sales(TTM) 36.99 | ||
Enterprise Value to Revenue 32.82 | Enterprise Value to EBITDA -0.15 | Shares Outstanding 43.30M | Shares Floating 37.39M |
Shares Outstanding 43.30M | Shares Floating 37.39M | ||
Percent Insiders 4.12 | Percent Institutions 27.13 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About NRX Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Wilmington, DE, United States | ||
IPO Launch date 2017-12-04 | Co-Founder, Chairman & CEO Dr. Jonathan C. Javitt M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 29 | Website https://www.nrxpharma.com |
Full time employees 29 | Website https://www.nrxpharma.com | ||
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.